ICE Bioscience Posters

Download

A new collaborative report from IARC. There were almost 20 million new cases of cancer and close to 10 million deaths from cancer in 2022. Despite an estimated increase to more than 2.31 million new cases, breast cancer became the second most common cancer type, after lung cancer. The most common subtype, hormone-receptor-positive/HER2-negative (HR+ or ER+/HER2-), accounts for 69% of all cases. Cyclin-dependent kinase (CDK) 4/6 inhibition in combination with endocrine therapy is the standard-of-care treatment for patients with advanced-stage HR+HER2- breast cancer. Cell cycle regulators with promising clinical potential include CDK2, CDK4, CDK7, PLK4, WEE1, PKMYT1, AURKA and TTK. Novel inhibitors of these targets, alone or in combination, may overcome CDK4/6 inhibitor resistance. Based on this, we have established a series of in vivo and in vitro assays on CDK family targets. On this basis, we have established a series of in vitro and in vivo experiments on CDK family targets, which can achieve high-throughput screening in vitro experiments, providing a faster screening strategy for CDKs inhibitors.